Literature DB >> 11013777

[Establishment of a national database for ICU-associated infections. First results from the "Krankenhaus-Infections-Surveillance-System" (KISS)].

C Geffers1, J Koch, D Sohr, A Nassauer, F Daschner, H Rüden, P Gastmeier.   

Abstract

OBJECTIVES: To establish a surveillance system as an element of internal quality management, participating intensive care units (ICUs) report their ICU-associated infection surveillance data for aggregation into a national database.
METHODS: In order to provide data on ICU-associated infections, a nosocomial surveillance system in German intensive care units (Krankenhaus-Infections-Surveillance-System (KISS)) started in 1997. The method of data collection is based on the (adult) ICU surveillance component from the National Nosocomial Infections Surveillance (NNIS)-System. Until now 113 German ICUs (most of them medical/surgical ICUs) were included in this system. We continuously collected and calculated the data from site-specific infections (device-associated pneumonias, blood stream infections and urinary tract infections).
RESULTS: There are now a total of 393,177 patient-days (100,015 patients) among them 176,415 ventilator-days, 295,221 central line-days and 316,799 urinary catheter-days in the data base. The data analysis showed the following device-associated infection rates: 11.2 pneumonias/1000 ventilator-days, 1.8 primary bloodstream infections/1000 central line-days and 4.0 urinary tract infections/1000 urinary catheter-days.
CONCLUSION: The project has reached high interest in Germany and animated more ICUs to take part or to apply the same method in order to use the reference data for comparison.

Entities:  

Mesh:

Year:  2000        PMID: 11013777     DOI: 10.1007/s001010070068

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  7 in total

1.  Surgical site infection - a European perspective of incidence and economic burden.

Authors:  David J Leaper; Harry van Goor; Jacqueline Reilly; Nicola Petrosillo; Heinrich K Geiss; Antonio J Torres; Anne Berger
Journal:  Int Wound J       Date:  2004-12       Impact factor: 3.315

2.  Effects of long-term routine use of selective digestive decontamination on antimicrobial resistance.

Authors:  Alexandra Heininger; Elisabeth Meyer; Frank Schwab; Matthias Marschal; Klaus Unertl; Wolfgang A Krueger
Journal:  Intensive Care Med       Date:  2006-08-08       Impact factor: 17.440

3.  Nosocomial infections and multidrug-resistant organisms in Germany: epidemiological data from KISS (the Hospital Infection Surveillance System).

Authors:  Christine Geffers; Petra Gastmeier
Journal:  Dtsch Arztebl Int       Date:  2011-02-11       Impact factor: 5.594

4.  Proposing an empirically justified reference threshold for blood culture sampling rates in intensive care units.

Authors:  André Karch; Stefanie Castell; Frank Schwab; Christine Geffers; Hannah Bongartz; Frank M Brunkhorst; Petra Gastmeier; Rafael T Mikolajczyk
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

5.  [Quality assurance in intensive care medicine. SARI-surveillance on antibiotic use and bacterial resistance in intensive care units].

Authors:  E Meyer; B Schroeren-Boersch; F Schwab; D Jonas; H Rüden; P Gastmeier; F D Daschner
Journal:  Anaesthesist       Date:  2004-05       Impact factor: 1.041

6.  [Periodic surveillance of nosocomial infections in two neurology intensive care units. A valuable tool for quality management in intensive care].

Authors:  D Zolldann; C Poetter; R Hilker; M Neveling; B Waitschies; W Klein; M Nolden-Koch; F Block; H M Wenchel; S W Lemmen
Journal:  Anaesthesist       Date:  2003-08       Impact factor: 1.041

7.  Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units.

Authors:  Elisabeth Meyer; Frank Schwab; Daniel Jonas; Henning Rueden; Petra Gastmeier; Franz D Daschner
Journal:  Intensive Care Med       Date:  2004-03-26       Impact factor: 17.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.